About this Research Topic
Despite their inherent heterogeneity blood cancers such as leukemia, lymphoma, and myeloma often share common mechanisms that are responsible for malignant transformation, cell growth, and cell resistance to cytotoxic therapies.
Chronic cellular stress is regularly present in normal blood cells and the cellular mechanisms dedicated to its management are frequently exploited during the process of malignant transformation. On one hand, the intrinsic dependence on stress-managing pathways may protect blood cancer cells from cell death; on the other hand, it renders the transformed cells addicted to those pathways, which are suitable for therapeutic targeting.
The current Research Topic aims to highlight the recent discoveries in cellular stress and blood cancer. We should look towards analyzing the most recent insights on the pathogenesis of various blood malignancies with related cellular stresses and bring forward the development of stress-managing molecular targets for therapeutic use.
This collection thus welcomes submissions in the form of Original Research, Review, and Mini-Review articles.
Specific themes that may be included but not limited to:
· Role of cellular stress (ER stress, autophagic stress, replication stress, oxidative stress, hypoxic stress) in normal and malignant blood cells
· Actual and potential therapeutic targeting of cellular stress in blood cancers, with emphasis on novel agents and immunotherapy
· A mix of biological notions and clinical implications are preferable in the contributions in order to attract the widest audience and stimulate discussion and interest in the topic.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology
Chronic cellular stress is regularly present in normal blood cells and the cellular mechanisms dedicated to its management are frequently exploited during the process of malignant transformation. On one hand, the intrinsic dependence on stress-managing pathways may protect blood cancer cells from cell death; on the other hand, it renders the transformed cells addicted to those pathways, which are suitable for therapeutic targeting.
The current Research Topic aims to highlight the recent discoveries in cellular stress and blood cancer. We should look towards analyzing the most recent insights on the pathogenesis of various blood malignancies with related cellular stresses and bring forward the development of stress-managing molecular targets for therapeutic use.
This collection thus welcomes submissions in the form of Original Research, Review, and Mini-Review articles.
Specific themes that may be included but not limited to:
· Role of cellular stress (ER stress, autophagic stress, replication stress, oxidative stress, hypoxic stress) in normal and malignant blood cells
· Actual and potential therapeutic targeting of cellular stress in blood cancers, with emphasis on novel agents and immunotherapy
· A mix of biological notions and clinical implications are preferable in the contributions in order to attract the widest audience and stimulate discussion and interest in the topic.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology
Keywords: malignant hematopoiesis, ER stress, Autophagy, Mitophagy, DNA replication stress, Oxydative stress, Telomere erosion, Immunogenic cell death, Hodgkin's Lymphoma, Non Hodgkin's Lymphomas, Multiple Myeloma and plasma cell dyscrasias, Acute Myeloid Leukemia
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
